Manufacturer of Controlled Substances; Notice of Registration, 28072-28073 [E7-9644]
Download as PDF
<![CDATA[
28072
Federal Register / Vol. 72, No. 96 / Friday, May 18, 2007 / Notices
Cambrex Charles City, Inc. to import the
basic class of controlled substance is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated
Cambrex Charles City, Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: May 14, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–9609 Filed 5–17–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: May 14, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–9625 Filed 5–17–07; 8:45 am]
BILLING CODE 4410–09–P
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated January 16, 2007, and
published in the Federal Register on
January 23, 2007, (72 FR 2907),
Cedarburg Pharmaceuticals, Inc., 870
Badger Circle, Grafton, Wisconsin
53024, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
I and II:
pwalker on PROD1PC71 with NOTICES
Drug
Tetrahydrocannabinols (7370) .....
Dihydromorphine (9145) ...............
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
Remifentanil (9739) ......................
17:06 May 17, 2007
Jkt 211001
Schedule
I
I
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cedarburg Pharmaceuticals, Inc. to
manufacture the listed basic class of
controlled substance is consistent with
the public interest at this time. DEA has
investigated Cedarburg Pharmaceuticals,
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with State
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
PO 00000
Frm 00054
Fmt 4703
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Manufacturer of Controlled
Substances; Notice of Registration
DEPARTMENT OF JUSTICE
Manufacturer of Controlled
Substances; Notice of Registration
VerDate Aug<31>2005
Dated: May 14, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–9642 Filed 5–17–07; 8:45 am]
Drug Enforcement Administration
Drug Enforcement Administration
By Notice dated October 25, 2006, and
published in the Federal Register on
November 1, 2006, (71 FR 64298),
Cambrex Charles City, Inc., 1205 11th
Street, Charles City, Iowa 50616, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Sufentanil (9740), a basic class of
controlled substance listed in schedule
II.
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cambrex Charles City, Inc. to
manufacture the listed basic class of
controlled substance is consistent with
the public interest at this time. DEA has
investigated Cambrex Charles City, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with State
and local laws, and a review of the
company’s background and history.
the basic classes of controlled
substances listed.
Sfmt 4703
By Notice dated November 21, 2006,
and published in the Federal Register
on December 1, 2006, (71 FR 69589–
69590), Chattem Chemicals, Inc., 3801
St. Elmo Avenue, Building 18,
Chattanooga, Tennessee 37409, made
application by renewal and by letter to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
I and II:
Drug
4–Methoxyamphetamine (7411) ...
Dihydromorphine (9145) ...............
Difenoxin (9168) ...........................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Pentobarbital (2270) .....................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Alfentanil (9737) ...........................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
Schedule
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
By letter dated February 15, 2007,
Chattem Chemicals has withdrawn their
request for N-Ethylamphetamine (1475),
Secobarbital (2315), 2,5–
Dimethoxyamphetamine (7396),
Diphenoxylate (9170), Opium Extracts
(9610), Opium Fluid Extract (9620),
Opium Tincture (9630), Opium
Powdered (9639), and Opium
Granulated (9640).
One comment has been received; this
comment has been noted and
considered by DEA.
E:\FR\FM\18MYN1.SGM
18MYN1
Federal Register / Vol. 72, No. 96 / Friday, May 18, 2007 / Notices
DEA has considered the factors in 21
U.S.C. 823(a) and determined that the
registration of Chattem Chemicals, Inc.
to manufacture the listed basic classes
of controlled substances is consistent
with the public interest at this time.
DEA has investigated Chattem
Chemicals, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: May 14, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–9644 Filed 5–17–07; 8:45 am]
DEA to bulk manufacture such a
substance, may file comments or
objections to the issuance of the
proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register
Representative(ODL), Washington, DC
20537, or any being sent via express
mail should be sent to Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative(ODL), 2401 Jefferson
Davis Highway, Alexandria, Virginia
22301; and must be filed no later than
July 17, 2007.
Dated: May 10, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–9608 Filed 5–17–07; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on July 28, 2006, Cody
Laboratories, Inc., 601 Yellowstone
Avenue, Cody, Wyoming 82414, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule I and II:
Drug
Schedule
pwalker on PROD1PC71 with NOTICES
Dihydromorphine (9145) ...............
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Cocaine (9041) .............................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Meperidine (9230) ........................
Oxymorphone (9652) ...................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
I
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans on manufacturing
the listed controlled substance in bulk
for sale to its customers.
Any other such applicant, and any
person who is presently registered with
VerDate Aug<31>2005
17:06 May 17, 2007
Jkt 211001
By Notice dated February 5, 2007 and
published in the Federal Register on
February 12, 2007, (72 FR 6578–6579),
Fisher Clinical Services Inc., 7554
Schantz Road, Allentown, Pennsylvania
18106, made application by letter to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
Noroxymorphone (9668), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance for analytical
research and clinical trials.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Fisher Clinical Services Inc. to import
the basic class of controlled substance is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated Fisher
Clinical Services Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
28073
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: May 14, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–9610 Filed 5–17–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated November 21, 2006
and published in the Federal Register
on December 1, 2006, (71 FR 69590),
Formulation Technologies LLC, 11400
Burnet Road, Suite 4010, Austin, Texas
78758, made application to the Drug
Enforcement Administration (DEA) to
be registered as an importer of Fentanyl
(9801), a basic class of controlled
substance listed in schedule II.
The company plans to import the
listed controlled substance for clinical
trials, research, analytical purposes and
distribution to its customers.
One objection was received; however,
it has subsequently been withdrawn.
DEA has considered the factors in 21
U.S.C. 823(a) and 952(a) and determined
that the registration of Formulation
Technologies LLC to import the basic
classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated
Formulation Technologies LLC to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
E:\FR\FM\18MYN1.SGM
18MYN1
]]>Agencies
[Federal Register Volume 72, Number 96 (Friday, May 18, 2007)]
[Notices]
[Pages 28072-28073]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-9644]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated November 21, 2006, and published in the Federal
Register on December 1, 2006, (71 FR 69589-69590), Chattem Chemicals,
Inc., 3801 St. Elmo Avenue, Building 18, Chattanooga, Tennessee 37409,
made application by renewal and by letter to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of the
basic classes of controlled substances listed in schedule I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
4-Methoxyamphetamine (7411)................ I
Dihydromorphine (9145)..................... I
Difenoxin (9168)........................... I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Methylphenidate (1724)..................... II
Pentobarbital (2270)....................... II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Hydrocodone (9193)......................... II
Meperidine (9230).......................... II
Dextropropoxyphene, bulk (non-dosage forms) II
(9273).
Morphine (9300)............................ II
Thebaine (9333)............................ II
Oxymorphone (9652)......................... II
Noroxymorphone (9668)...................... II
Alfentanil (9737).......................... II
Sufentanil (9740).......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution to its customers.
By letter dated February 15, 2007, Chattem Chemicals has withdrawn
their request for N-Ethylamphetamine (1475), Secobarbital (2315), 2,5-
Dimethoxyamphetamine (7396), Diphenoxylate (9170), Opium Extracts
(9610), Opium Fluid Extract (9620), Opium Tincture (9630), Opium
Powdered (9639), and Opium Granulated (9640).
One comment has been received; this comment has been noted and
considered by DEA.
[[Page 28073]]
DEA has considered the factors in 21 U.S.C. 823(a) and determined
that the registration of Chattem Chemicals, Inc. to manufacture the
listed basic classes of controlled substances is consistent with the
public interest at this time. DEA has investigated Chattem Chemicals,
Inc. to ensure that the company's registration is consistent with the
public interest. The investigation has included inspection and testing
of the company's physical security systems, verification of the
company's compliance with State and local laws, and a review of the
company's background and history. Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33, the above named company is
granted registration as a bulk manufacturer of the basic classes of
controlled substances listed.
Dated: May 14, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-9644 Filed 5-17-07; 8:45 am]
BILLING CODE 4410-09-P
